ArticleStem cells (Dayton, Ohio)2009
Generation of T lineage cells from human embryonic stem cells in a feeder free system.
Article in Stem cells (Dayton, Ohio), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- 'Off the shelf' immunotherapies: Generation and application of pluripotent stem cell-derived immune cells.Cell proliferation · 2023Review
- Improved Isolation and Culture of Urine-Derived Stem Cells (USCs) and Enhanced Production of Immune Cells from the USC-Derived Induced Pluripotent Stem Cells.Journal of clinical medicine · 2020Article
- 3,2'-Dihydroxyflavone Improves the Proliferation and Survival of Human Pluripotent Stem Cells and Their Differentiation into Hematopoietic Progenitor Cells.Journal of clinical medicine · 2020Article
- iPSC-Based Modeling of RAG2 Severe Combined Immunodeficiency Reveals Multiple T Cell Developmental Arrests.Stem cell reports · 2020Article
- Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells.Cell stem cell · 2019Article
- Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.Stem cells (Dayton, Ohio) · 2018Review
- Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model.Scientific reports · 2017Article
- Molecular Analysis of Neutrophil Differentiation from Human Induced Pluripotent Stem Cells Delineates the Kinetics of Key Regulators of Hematopoiesis.Stem cells (Dayton, Ohio) · 2016Article
- Mesodermal and hematopoietic differentiation from ES and iPS cells.Stem cell reviews and reports · 2013Review
- Generation of mature hematopoietic cells from human pluripotent stem cells.International journal of hematology · 2012Review
- Brief report: efficient generation of hematopoietic precursors and progenitors from human pluripotent stem cell lines.Stem cells (Dayton, Ohio) · 2011Article
- Stem cell-based anti-HIV gene therapy.Virology · 2011Review
- Potential clinical applications for human pluripotent stem cell-derived blood components.Stem cells international · 2011Article
- Comparative study of hematopoietic differentiation between human embryonic stem cell lines.PloS one · 2011Article
- Stem cell-based approaches to treating HIV infection.Current opinion in HIV and AIDS · 2011Review
- Temporal specification of blood progenitors from mouse embryonic stem cells and induced pluripotent stem cells.Development (Cambridge, England) · 2010Article
- Leveraging human genetics to develop future therapeutic strategies in rheumatoid arthritis.Rheumatic diseases clinics of North America · 2010Review
- Hematopoiesis from pluripotent stem cell lines.International journal of hematology · 2010Review
- GWASs and the age of human as the model organism for autoimmune genetic research.Genome biology · 2010Article
- Autologous blood cell therapies from pluripotent stem cells.Blood reviews · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Human embryonic stem cells (hESC) have the potential to revolutionize certain medical treatments, including T-cell-based therapies. However, optimal approaches to develop T cells from hESC are lacking. In this report, we show that T-cell progenitors can be derived from hESC cultured as embryoid bodies (EBs). These EB-derived T-cell progenitors give rise to phenotypically and functionally normal cells of the T lineage when transferred into human thymic tissue implanted in immunocompromised mice, suggesting that introduction of these progenitors into patients may also yield functional T cells. Moreover, hematopoietic progenitors demonstrating T-cell potential appeared to be CD45+/CD34+, resembling those found in normal bone marrow. In contrast to T cells developed from hESC cocultured on murine stromal cells, the EB-derived T cells also expressed normal levels of CD45. Importantly, the EB system eliminates the previous need for murine cocultures, a key impediment to developing a protocol for T-cell progenitor derivation suitable for clinical use. Furthermore, following lentiviral-mediated introduction of a vector expressing enhanced green fluorescent protein into hESC, stable transgene expression was maintained throughout differentiation, suggesting a potential for gene therapy approaches aimed at the augmentation of T-cell function or treatment of T-cell disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.